Trial In Pediatric Patients With Familial Adenomatous Polyposis (FAP)
Public ClinicalTrials.gov record NCT00585312. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III Placebo-Controlled Trial Of Celecoxib In Genotype Positive Subjects With Familial Adenomatous Polyposis
Study identification
- NCT ID
- NCT00585312
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Industry
- Enrollment
- 106 participants
Conditions and interventions
Conditions
Interventions
- Celecoxib Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 10 Years to 17 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2006
- Primary completion
- Sep 30, 2013
- Completion
- Sep 30, 2013
- Last update posted
- Feb 20, 2021
2006 – 2013
United States locations
- U.S. sites
- 23
- U.S. states
- 8
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Chicago | Illinois | 60612 | — |
| Pfizer Investigational Site | Ann Arbor | Michigan | 48109 | — |
| Pfizer Investigational Site | Omaha | Nebraska | 68114 | — |
| Pfizer Investigational Site | New York | New York | 10017 | — |
| Pfizer Investigational Site | New York | New York | 10022 | — |
| Pfizer Investigational Site | New York | New York | 10065 | — |
| Pfizer Investigational Site | Chagrin Falls | Ohio | 44136 | — |
| Pfizer Investigational Site | Cincinnati | Ohio | 45229 | — |
| Pfizer Investigational Site | Cleveland | Ohio | 44122 | — |
| Pfizer Investigational Site | Cleveland | Ohio | 44195 | — |
| Pfizer Investigational Site | Elyria | Ohio | 44035 | — |
| Pfizer Investigational Site | Independence | Ohio | 44131 | — |
| Pfizer Investigational Site | Lakewood | Ohio | 44107 | — |
| Pfizer Investigational Site | Lorain | Ohio | 44053 | — |
| Pfizer Investigational Site | Solon | Ohio | 44138 | — |
| Pfizer Investigational Site | Strongsville | Ohio | 44136 | — |
| Pfizer Investigational Site | Westlake | Ohio | 44145 | — |
| Pfizer Investigational Site | Willoughby Hills | Ohio | 44094 | — |
| Pfizer Investigational Site | Wooster | Ohio | 44691 | — |
| Pfizer Investigational Site | Nashville | Tennessee | 37232 | — |
| Pfizer Investigational Site | Houston | Texas | 77030-4990 | — |
| Pfizer Investigational Site | Salt Lake City | Utah | 84112 | — |
| Pfizer Investigational Site | Salt Lake City | Utah | 84132 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 19 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00585312, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 20, 2021 · Synced May 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00585312 live on ClinicalTrials.gov.